The company OpZira Inc. has launched to advance ophthalmic diagnostics. The company plans to deliver innovative technologies with the ability to enhance the detection and monitoring of ocular disease, which can empower clinicians.

Clark Tedford, PhD, President & CEO of OpZira, spoke to the company’s mission, saying, “OpZira was founded to bridge the gap between groundbreaking research and practical clinical tools. Our mission is to give eye care professionals the technology they need to detect ocular diseases earlier and monitor them more effectively.”¹

The creation of this company follows Alcon’s acquisition of LumiThera and its Valeda Light Delivery System, the first and only FDA-authorized treatment for dry age-related macular degeneration (AMD). As part of the transaction, LumiThera’s diagnostic product lines were spun off to LumiThera shareholders, leading to the establishment of OpZira, Inc.¹

Eleonora Lad, MD, PhD, Duke University Medical Center spoke to the success of LumiThera and how OpZira’s tools may help determine treatment timelines. In the news release¹, she said, “Building on the LumiThera team’s success in developing the Valeda treatment for early to intermediate dry AMD patients, the OpZira technologies may provide early detection and ongoing monitoring which are important for optimizing patient outcomes. Now that there are approved treatment options for dry AMD, having tools that provide objective data to help determine when and how often to treat patients is critical.”

What products does OpZira’s offer?

According to the company’s press release, OpZira’s initial products include the AdaptDx Pro and the NOVA Vision Testing System.

AdaptDx Pro

A wearable dark adaptometer that leverages AI to ensure a consistent patient experience. Impaired dark adaptation speed, a key early indicator of rod-mediated dysfunction, is often among the first functional signs of retinal disease. AdaptDx Pro is available in the US.¹

NOVA™ Vision Testing System

A robust electrophysiology platform providing objective assessments of the entire visual and neuro-visual pathway. The Visual Evoked Potential (VEP) module is available in the US. and select international markets, while the Electroretinography (ERG) module is available outside the US.¹

Alcon's LumiThera acquistion

Previously, Ophthalmology Times reported that Alcon is continuing its trend of acquisitions in 2025 with the announcement that the company will acquire LumiThera, Inc. and its photobiomodulation (PBM) device for the treatment of early and intermediate dry age-related macular degeneration (AMD).²

In that reporting, it was noted that the planned acquisition dis not include the acquisition of AdaptDx and Nova/Diopsys diagnostic devices. Those devices are planned to be separated and spun off to LumiThera’s shareholders prior to Alcon’s acquisition and will continue to be marketed and sold by the LumiThera spin-off. The companies anticipate the acquisition to be completed in the third quarter of 2025.²

Reference:

1. OpZira, Inc. Launches to Advance Ophthalmic Diagnostics with Innovative Medical Device Portfolio. OpZira, Inc. News Release. September 3, 2025. Accessed September 4, 2025. https://www.businesswire.com/news/home/20250903785229/en/OpZira-Inc.-Launches-to-Advance-Ophthalmic-Diagnostics-with-Innovative-Medical-Device-Portfolio

2. Harp, MD. Alcon to acquire LumiThera and its photobiomodulation device for the treatment of dry AMD. Ophthalmology Times. July 7, 2025. Accessed September 4, 2025. https://www.ophthalmologytimes.com/view/alcon-to-acquire-lumithera-and-its-photobiomodulation-device-for-the-treatment-of-dry-amd